Clinical Trial Update: Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This terminated Phase 1/2 trial evaluated low-dose oral clofarabine for IPSS INT-1/INT-2 or high-risk myelodysplastic syndromes and chronic myelomonocytic leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Clolar (Clofarabine)

Snippet

Sponsor: University of Utah | Conditions: Cancer, Chronic Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-06-01